BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Extra | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BC Week In Review | Mar 8, 2019
Company News

BeiGene, Ambrx partner to discover, develop cancer biologics

BeiGene partnered with Ambrx to discover cancer therapeutics using the latter's site-specific conjugation technology. The technology uses cell lines engineered with transfer RNAs (tRNAs)/tRNA synthase that can incorporate non-natural amino acids into specified peptide and...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright,...
BC Extra | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China...
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BC Week In Review | Jan 5, 2018
Company News

Ambrx gets Chinese rights to Tracon's carotuximab

Cancer company Tracon Pharmaceuticals Inc. (NASDAQ:TCON) granted Ambrx Inc. (La Jolla, Calif.) exclusive rights to develop and commercialize carotuximab (IV TRC105) in China, Hong Kong, Macau and Taiwan for all indications excluding ophthalmology, which are...
Items per page:
1 - 10 of 109
BioCentury | May 17, 2019
Emerging Company Profile

89bio: standing out in the NASH crowd

89bio thinks it can differentiate itself from companies targeting NASH as an inflammatory and fibrotic disease by attacking it as a metabolic disorder and addressing its root cause with an FGF analog that could be...
BioCentury | Apr 6, 2019
Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
BC Innovations | Mar 15, 2019
Tools & Techniques

Synthetic solutions for immuno-oncology

Synthorx Inc. is poised to enter the clinic this year with an IL-2 therapy that could validate its synthetic DNA platform. Marrying its click chemistry and unnatural amino acid technology with pegylation, the company is...
BC Extra | Mar 12, 2019
Company News

Management tracks: Inovio, Sangamo, Innate

Inovio CMO Mark Bagarazzi has left the company. Inovio Pharmaceuticals Inc. (NASDAQ:INO) said a newly formed medical council -- VPs of Clinical Development Prakash Bhuyan, Jeffrey Skolnik and Scott White -- will now oversee the...
BC Week In Review | Mar 8, 2019
Company News

BeiGene, Ambrx partner to discover, develop cancer biologics

BeiGene partnered with Ambrx to discover cancer therapeutics using the latter's site-specific conjugation technology. The technology uses cell lines engineered with transfer RNAs (tRNAs)/tRNA synthase that can incorporate non-natural amino acids into specified peptide and...
BioCentury | Jan 5, 2019
Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
BC Week In Review | Oct 26, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target is RMB1.5 billion ($216.3 million). According to China Everbright,...
BC Extra | Oct 23, 2018
Financial News

First close for China Everbright’s new healthcare fund

China Everbright Ltd. (HKSE:165) completed the first close of its third healthcare fund, raising more than RMB800 million ($115.4 million). The CEL Healthcare Fund III's target size is RMB1.5 billion ($216.3 million). According to China...
BC Extra | Jan 9, 2018
Company News

Management tracks: OncoMed, Neurocrine

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman, President and CEO Paul Hastings has resigned. The company is seeking a replacement. Perry Karsen will serve as chairman. Hastings began a medical leave of absence on...
BC Week In Review | Jan 5, 2018
Company News

Ambrx gets Chinese rights to Tracon's carotuximab

Cancer company Tracon Pharmaceuticals Inc. (NASDAQ:TCON) granted Ambrx Inc. (La Jolla, Calif.) exclusive rights to develop and commercialize carotuximab (IV TRC105) in China, Hong Kong, Macau and Taiwan for all indications excluding ophthalmology, which are...
Items per page:
1 - 10 of 109